1 / 50

Prostate Cancer Expected Management & curative treatment

Prostate Cancer Expected Management & curative treatment. Dr. Abdullah A. Ghazi (R5) KSMC. Incidence of PC. Mortality of PC. Life time risk 17% Dying 3.6% Doubling time 2-4y. 42% of men <50y die from other cause. Watchful waiting: Active surveillance:. Life expectancy in US, 2008.

ailish
Download Presentation

Prostate Cancer Expected Management & curative treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prostate CancerExpected Management & curative treatment Dr. Abdullah A. Ghazi (R5) KSMC

  2. Incidence of PC

  3. Mortality of PC • Life time risk 17% • Dying 3.6% • Doubling time 2-4y. • 42% of men <50y die from other cause.

  4. Watchful waiting: • Active surveillance:

  5. Life expectancy in US, 2008

  6. 157 pt. • T1c. • 0.2ml • GS ≤6 • No grade 4 or 5 by biopsy. • PSAD 0.1ng/ml/gm, <3 cores with tumor, not > 50%. • PSAD 0.15ng/ml/gm, <3mm cancer • Predict value for a significant disease 95% • 73% of their patients were insignificant tumor.

  7. Active Surveillance • The aim is to avoid unnecessary treatment on low-grade tumor that not affect the life or health for the next 5-10y. • Life expectancy > 10y have risk of metastasis. • Compliance.

  8. Active Surveillance • 31% will progress (GS, %specimen involvement, NO + biopsy

  9. Active Surveillance • About ½ of the patient on AS remain free of progression within 10y. • Definitive treatment is appropriate in those with progression.

  10. 299 pt. • 55M F/U, 60% remaining on AS. • At 8y: OS 85% DSS 99%

  11. AS for whom? • Eligibility criteria: • Clinically confined PCa (T1-T2). • Gleason score < 7. • PSA < 15-20 ng/mL . • Prostatic biopsy (at 5y 83% have N sample)

  12. AS progression • Criteria to define cancer progression: • PSAD: between < 2 and < 4 years; • Gleason score progression to > 7 at re-biopsy, at intervals ranging from 1-4 years.

  13. SUMMARY • Pt with life expectancy <10y, GS ≤ 6 are suitable for AS. • AS may be safe alternative to immediate treatment in compliant men with low risk of progression.

  14. Prostate Cancer • Immediate treatment → risk of overtreatment. • AS → risk of progression

  15. Prostate Cancer • The pt with AS may become anxious with an untreated cancer. • AS is more appropriate for old pt’s with limited life expectancy.

  16. Radical Prostatectomy • It is still the gold standard. • Wide use or RP due to: • Early detection (PSA & TRUS). • Anatomical development of preserve cavernosal nerve & external sphincter. (90%).

  17. Radical Prostatectomy • Advantage: • Cure with minimal damage. • Accurate staging. • Smooth post-op course. • Rare need blood transfusion. • Hospital stay 1-3 days. • ↓local recurrence & distal metastasis vs WW. • Salvage of recurrence with RT.

  18. Radical Prostatectomy • Disadvantage: • hospitalization. • Recovery period. • Risk of ED & incontinence.

  19. Radical Prostatectomy • Surgical approach • Perineal: • Retropubic: • Laparoscopic: • Robotic:

  20. Radical Prostatectomy • Salvage RP: • Has higher complication rate. • Incontinence 44% • Bladder neck contraction 22% Ward et al 2005

  21. Radical Prostatectomy • Selection of pt for RP: • Life expectancy at least 10y (upper limit 75y). • Pre-op clinical & pathologic parameter.

  22. Radical Prostatectomy • Contraindication of nerve sparing: • Extensive cancer in biopsy (>50%). • PSA > 10ng/ml • GS > 7 • Site of the tumor • T2 disease. • Adhesion of the NV bundle to the prostate. • Poor erection pre-op. • Lack of sexual relationship. • Medical illness adverse erection.

  23. Radical Prostatectomy • Post-op ED should be D/W pt. • Complication of adjuvant therapy (HT, RT).

  24. Radical Prostatectomy • Adverse prognostic feature: • Perineural invasion. • Extracapsular extension. • + surgical margin. • SV invasion. • L.N. metastasis. • High PSA is the early sign of recurrence.

  25. Radical Prostatectomy • Complications: • Continent 90%. • Eerection: 95% 40y 50% 70y. • It return partially at 3-6M up to 3y. • Complications < 10%. • Mortality rare.

  26. Radical Prostatectomy • Complication: • Early: • Hemorrhage • Injury to adjacent organs. • Urinary leak & fistula. • Thromboembolic & CVA events. • UTI. • Lymphocele. • Wound complication. • Late: • ED • Incontinence. • Urethral stricture.

  27. RP is a reasonable option in a selected pt. • The pt must be inform about multimodal approach. • T3N0M0 PC (431pt) • Adjuvant RT • Better met-free survival with RT. Thompson • Adjuvant ADT vs observation in +LN • 11.9 f/u • Better OS with ADT. Messing et al

  28. Pelvic LN dissection • Limited “Obturator. Ext.iliac”, 8-10. • Extend, 20. • Therapeutic role • Morbidity of eLND (x3) • Lymphoedema. • Lymphocele. • DVT. • PE

  29. Pelvic LN dissection

  30. Neoadjuvant HT with RP • Effect on pathology results ? • Pathology down-staging. • More organ confined. • Less + margin. • Less LN involvement. • Effect on OS & DFS.

  31. Adjuvant HT with RP • No survival advantage.

  32. RADIATION THERAPY • 3D-CRT • IMRT • It is comparable result with RP (?? Not the same end point). • Standard dose 76-80Gy. • IMRT limit outside radiation by 1-1.5cm.

  33. RADIATION THERAPY • Side effect: • Microvascular injury. • IBS, rectal bleeding, bladder irritability, hematuria. • Relative C/I: • Prior TURP (urethral stricture, seeds of brachiotherapy not hold). • Severe LUTS. • IBD.

  34. RADIATION THERAPY WITH HORMONAL • They include the locally advanced prostate cancer (T2c-4) • STAD-RT vs LTAD-RT. • Improvement of all end point with LTAD-RT except OS.

  35. RADIATION THERAPY WITH HORMONAL • Increase OS in high risk group (more with LAD-RT).

  36. RADIATION THERAPY • Endpoints for failure: • PSA ↓ within 2-3y. • PSA measurement Q6M. • PSA bounce. • Definition of PSA failure.

  37. RADIATION THERAPY • Result: • 50% cure rate for clinically localized PC. • HT for 2-3y can be given after RT. • EB-RT can combined with brachytherapy.

  38. BRACHYTHERAPY • Indication: • stage cT1b- T2a N0, M0; • Gleason score < 6 assessed on a sufficient number of random biopsies. • Initial PSA level of < 10 ng/mL. • < 50% of biopsy cores involved with cancer. • Prostate volume of < 50 cm3. • IPSS < 12.

  39. BRACHYTHERAPY • To be given under GA or regional anesthesia. • Ioden-125 (145Gy), palladium-103(125Gy). • CT scan after implant. • Results: • Cancer control: 5y 85% 8y 80% progression-free survival rate.

  40. BRACHYTHERAPY • S/E: • Urinary symptoms. • AUR 22%. • Need TURP 10% (risk of incontinence 20-40%). • 62-86% preserve erection. • Proctitis, rectal injury. • Migration. • Rectourethral fistula.

  41. ADJUVANT RT AFTER RP • Given 67-64Gy. • Wait 3-4M. • Recent study → benefit. • Option: RT vs wait for PSA failure. • Most likely benefit is the + margin & extracapsular invasion.

  42. ?? • Definition of PSA failure: • Post RP • Post RT

  43. http://www.youtube.com/watch?v=A-5RiAxfbRY

More Related